Research analysts at JMP Securities initiated coverage on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report issued on Thursday, MarketBeat reports. The brokerage set an “outperform” rating on the stock.
A number of other research firms also recently weighed in on NTLA. Barclays lifted their target price on Intellia Therapeutics from $33.00 to $46.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 7th. BidaskClub raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 9th. ValuEngine downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, December 12th. Finally, TheStreet downgraded Intellia Therapeutics from a “c-” rating to a “d” rating in a research report on Thursday, December 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Intellia Therapeutics currently has an average rating of “Buy” and a consensus target price of $33.00.
Shares of Intellia Therapeutics (NASDAQ NTLA) opened at $32.80 on Thursday. The stock has a market capitalization of $1,261.20, a PE ratio of -21.32 and a beta of 2.42. Intellia Therapeutics has a 1 year low of $11.15 and a 1 year high of $35.99.
Institutional investors and hedge funds have recently made changes to their positions in the business. Nationwide Fund Advisors lifted its stake in Intellia Therapeutics by 117.7% during the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock worth $129,000 after purchasing an additional 4,351 shares during the period. MetLife Investment Advisors LLC bought a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $146,000. The Manufacturers Life Insurance Company raised its stake in shares of Intellia Therapeutics by 451.2% in the second quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock valued at $212,000 after acquiring an additional 10,825 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $230,000. Finally, New York State Common Retirement Fund raised its stake in shares of Intellia Therapeutics by 109.7% in the second quarter. New York State Common Retirement Fund now owns 15,100 shares of the company’s stock valued at $242,000 after acquiring an additional 7,899 shares during the last quarter. Hedge funds and other institutional investors own 68.14% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Intellia Therapeutics (NTLA) Receives New Coverage from Analysts at JMP Securities” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/08/intellia-therapeutics-ntla-earns-outperform-rating-from-analysts-at-jmp-securities.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.